| Literature DB >> 35345495 |
Bing-Mei Zhou1, Zhao-Lei Qiu1, Kai-Xuan Niu1, Yin-E Wang1, Fu-Chen Jie1.
Abstract
Background: This study aims to investigate the risk factors of pleural effusion (PE) secondary to severe acute pancreatitis (SAP) and to build a nomogram model.Entities:
Year: 2022 PMID: 35345495 PMCID: PMC8957464 DOI: 10.1155/2022/4199209
Source DB: PubMed Journal: Emerg Med Int ISSN: 2090-2840 Impact factor: 1.112
Univariate analysis of risk factors for PE secondary to SAP.
| Indexes | Control ( = 157) | PE secondary to SAP ( |
|
|
|---|---|---|---|---|
| Age | 50.59 ± 18.63 | 51.54 ± 18.16 | 0.348 | 0.728 |
| BMI | 22.66 ± 1.45 | 22.68 ± 1.02 | 0.089 | 0.929 |
|
| ||||
| Male | 96 (61.15) | 38 (58.46) | 0.139 | 0.710 |
| Female | 61 (38.85) | 27 (41.54) | ||
| Fatty liver ( | 47 (29.94) | 24 (36.92) | 1.032 | 0.310 |
| Hyperlipidemia ( | 22 (14.01) | 5 (7.69) | 1.719 | 0.190 |
| Cholecystitis ( | 28 (17.83) | 12 (18.46) | 0.012 | 0.912 |
| Smoking ( | 25 (15.92) | 12 (18.46) | 0.213 | 0.644 |
| Alcohol ( | 15 (9.55) | 12 (18.46) | 3.141 | 0.065 |
| WBC (×109/L) | 14.02 ± 4.11 | 15.45 ± 4.88 | 2.225 | 0.027 |
| NEU | 80.88 ± 8.75 | 84.86 ± 11.48 | 2.801 | 0.006 |
| ALB (g/L) | 38.98 ± 5.52 | 34.24 ± 5.96 | 5.680 | <0.001 |
| FIB (mg/dl) | 5.33 ± 0.89 | 6.05 ± 0.90 | 5.432 | 0.013 |
| GLU (mmol/L) | 7.61 ± 2.78 | 6.82 ± 0.98 | 2.254 | <0.001 |
| CRP (mg/L) | 102.73 ± 22.36 | 113.64 ± 19.46 | 3.431 | 0.025 |
| AMY (U/L) | 173.16 ± 20.39 | 169.11 ± 17.46 | 1.401 | 0.001 |
| LIP (U/L) | 1232.34 ± 371.89 | 993.12 ± 83.94 | 5.126 | 0.163 |
| APACHE-II score | 20.47 ± 2.74 | 22.03 ± 2.21 | 4.072 | <0.001 |
| SOFA score | 4.87 ± 1.31 | 9.58 ± 3.61 | 14.279 | <0.001 |
Multivariate analysis of risk factors for PE secondary to SAP.
| Index | B | SE | Wald |
| OR (95% CI) |
|---|---|---|---|---|---|
| Age | −0.028 | 0.021 | 1.779 | 0.182 | 0.973 (0.934∼1.013) |
| BMI | −0.109 | 0.245 | 0.198 | 0.656 | 0.897 (0.554∼1.450) |
| Gender | 0.888 | 0.736 | 1.456 | 0.228 | 2.431 (0.574∼10.284) |
| Fatty liver ( | −1.512 | 0.863 | 3.074 | 0.080 | 0.220 (0.041∼1.195) |
| Hyperlipidemia ( | 1.652 | 1.562 | 1.119 | 0.290 | 5.218 (0.244∼111.394) |
| Cholecystitis ( | −0.167 | 1.018 | 0.027 | 0.870 | 0.846 (0.115∼6.220) |
| Smoking (n (%)) | 0.284 | 0.966 | 0.086 | 0.769 | 1.328 (0.200∼8.813) |
| Alcohol ( | 0.542 | 1.339 | 0.164 | 0.686 | 1.720 (0.125∼23.740) |
| WBC (×109/L) | 0.036 | 0.076 | 0.226 | 0.634 | 1.037 (0.894∼1.203) |
| NEU | 0.054 | 0.041 | 1.774 | 0.183 | 1.056 (0.975∼1.143) |
| ALB (g/L) | −0.187 | 0.061 | 9.260 | 0.002 | 0.830 (0.736∼0.936) |
| FIB (mg/dl) | 1.520 | 0.477 | 10.154 | 0.001 | 4.573 (1.795∼11.648) |
| GLU (mmol/L) | −0.137 | 0.181 | 0.575 | 0.448 | 0.872 (0.612∼1.243) |
| CRP (mg/L) | 0.045 | 0.018 | 6.114 | 0.013 | 1.046 (1.009∼1.083) |
| AMY (U/L) | −0.008 | 0.019 | 0.187 | 0.666 | 0.992 (0.957∼1.029) |
| LIP (U/L) | 0.394 | 0.150 | 6.931 | 0.008 | 1.484 ( 1.106∼1.990) |
| APACHE-II score | 1.111 | 0.206 | 29.160 | 0.000 | 3.038 (2.030∼4.548) |
| SOFA score | 0.904 | 0.128 | 49.535 | 0.000 | 2.472 (1.920∼3.177) |
| Constant | −23.564 | 9.701 | 5.900 | 0.015 | 0.000 |
Figure 1The developed nomogram of PE secondary to SAP risk.
Figure 2ROC curve of the developed nomogram model for predicting the PE secondary to SAP.